Odyssey Therapeutics, Inc. (ODTX): who owns it and who trades it
As of Nov 16, 2026, ODTX insiders reported 3 open-market sales worth $32K and 9 purchases worth $75.3M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Simeon George (10% owner), with $32K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Odyssey Therapeutics
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ODTX
59 funds and institutions reported ODTX shares worth $653M at the end of Q2 2026, about 73% of the company. The largest holder is FMR LLC (Fidelity) with 10.8%.
Funds and institutions (13F) 73%Everyone else 27%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 5.18M | 10.78% | $96.9M | – |
| SR One Capital Management, LP | 3.79M | 7.90% | $71M | – |
| Tpg Gp A, LLC | 3.69M | 7.68% | $69M | – |
| Lightspeed Management Company, L.l.c. | 3.61M | 7.51% | $67.5M | – |
| Orbimed Advisors LLC | 3.00M | 6.25% | $56.2M | – |
| Sanofi | 1.99M | 4.15% | $37.3M | – |
| Deerfield Management Company, L.P. | 1.05M | 2.18% | $19.6M | – |
| Sands Capital Alternatives, LLC | 875,000 | 1.82% | $16.4M | – |
| Hhlr Advisors, Ltd. | 831,656 | 1.73% | $15.6M | – |
| General Catalyst Group Management, LLC | 810,272 | 1.69% | $15.2M | – |
| Affinity Asset Advisors, LLC | 766,346 | 1.60% | $14.3M | – |
| Adage Capital Partners Gp, L.l.c. | 725,000 | 1.51% | $13.6M | – |
| Vanguard Capital Management LLC | 720,440 | 1.50% | $13.5M | – |
| Foresite Capital Management V, LLC | 713,105 | 1.48% | $13.3M | – |
| Vivo Capital, LLC | 575,000 | 1.20% | $10.8M | – |
| EcoR1 Capital, LLC | 555,555 | 1.16% | $10.4M | – |
| Logos Global Management LP | 521,736 | 1.09% | $9.8M | – |
| Marshall Wace, LLP | 492,697 | 1.03% | $9.2M | – |
| T. Rowe Price Associates | 471,987 | 0.98% | $8.8M | – |
| Catalio Capital Management, LP | 457,839 | 0.95% | $8.6M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ODTX insiders reported $75.3M of open-market purchases and $32K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | James G Coulter +2 | Other | Purchase | 1.39M | $18.00 | $25M | Form 4 |
| May 11, 2026 | Simeon George +1 | 10% owner | Purchase | 200,000 | $18.00 | $3.6M | Form 4 |
| May 11, 2026 | Simeon George +1 | 10% owner | Sale | 1,065 | $18.00 | $19.2K | Form 4 |
| May 11, 2026 | Simeon George +1 | 10% owner | Purchase | 222,222 | $18.00 | $4M | Form 4 |
| May 11, 2026 | Simeon George +1 | 10% owner | Sale | 277 | $18.00 | $5K | Form 4 |
| May 11, 2026 | Simeon George +1 | 10% owner | Purchase | 133,333 | $18.00 | $2.4M | Form 4 |
| May 11, 2026 | Simeon George +1 | 10% owner | Sale | 438 | $18.00 | $7.9K | Form 4 |
| May 11, 2026 | Nan (LN) Li | Director | Purchase | 1.11M | $18.00 | $20M | Form 4 |
| May 11, 2026 | Shelley Chu | Director | Purchase | 11,111 | $18.00 | $200K | Form 4 |
| May 8, 2026 | Dimension Capital II, L.P. | Director | Purchase | 1.11M | $18.00 | $20M | Form 4 |
| May 8, 2026 | Jeffrey M Leiden | Director | Purchase | 5,000 | $20.00 | $100K | Form 4 |
| May 8, 2026 | Jason Haas | CFO | Purchase | 1,000 | $20.00 | $20K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| James G Coulter | Other | $25M | – | May 11, 2026 |
| Nan (LN) Li | Director | $20M | – | May 11, 2026 |
| Dimension Capital II, L.P. | Director | $20M | – | May 8, 2026 |
| Simeon George | 10% owner | $10M | $32K | May 11, 2026 |
| Shelley Chu | Director | $200K | – | May 11, 2026 |
| Jeffrey M Leiden | Director | $100K | – | May 8, 2026 |
| Jason Haas | Chief Financial Officer | $20K | – | May 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ODTX short interest
Moderate short interest. 7.0% of ODTX shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 3770%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.35M ODTX shares were sold short, 7.0% of the shares outstanding, up 2.0% from the report before. At the average daily volume of 216,970 shares, buying them all back would take about 15.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.35M | 6.97% | +2% | 216,970 | 15.4 |
| Oct 15, 2026 | 3.28M | 6.83% | +6% | 265,047 | 12.4 |
| Sep 30, 2026 | 3.11M | 6.47% | +41% | 551,207 | 5.6 |
| Sep 15, 2026 | 2.21M | 4.60% | No change | 204,876 | 10.8 |
| Aug 31, 2026 | 2.21M | 4.60% | -2% | 172,371 | 12.8 |
| Aug 14, 2026 | 2.25M | 4.68% | -1% | 120,560 | 18.7 |
| Jul 31, 2026 | 2.27M | 4.73% | +14% | 234,658 | 9.7 |
| Jul 15, 2026 | 1.99M | 4.15% | +11% | 306,320 | 6.5 |
| Jun 30, 2026 | 1.80M | 3.74% | +34% | 487,843 | 3.7 |
| Jun 15, 2026 | 1.34M | 2.80% | +161% | 282,980 | 4.8 |
| May 29, 2026 | 514,441 | – | +495% | 335,136 | 1.5 |
| May 15, 2026 | 86,503 | – | – | 426,652 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Odyssey Therapeutics company events
Odyssey Therapeutics filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 20, 2026AnnouncementShared information with investors. Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 23, 2026AnnouncementShared information with investors. Filing
- Jun 17, 2026ResultsReleased financial results. Filing
- May 11, 2026AgreementOdyssey Therapeutics, Inc. entered into a Share Purchase Agreement with TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder of the Company, for the purchase of an aggregate of 1,388,889 shares of the Company’s common stock, par value $0.001, at a per share price equal to the… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold ODTX
2 of the 50 well-known investors we track reported holding ODTX in their latest 13F filing. The largest position is Ken Griffin's, worth $2.2M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 99,926 | $2.2M | 0.0% | -55% |
| Israel Englander · Millennium Management | Q3 2026 | 26,392 | $586K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ODTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 13.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 13.0% |
Questions about Odyssey Therapeutics, Inc. (ODTX) stock
Who owns the most ODTX stock?
The largest reported owner of Odyssey Therapeutics, Inc. (ODTX) is FMR LLC (Fidelity), with 10.8% of the company. In total, 59 funds and institutions reported holding ODTX at the end of Q2 2026, together about 73% of the shares. See the largest owners.
Are ODTX insiders buying or selling?
In the last 12 months, ODTX insiders reported 9 open-market purchases worth $75.3M and 3 sales worth $32K. The latest trade was on May 11, 2026. See every trade.
What is the short interest in ODTX?
As of Oct 30, 2026, 3.35M ODTX shares were sold short, 7.0% of the shares outstanding, up 2.0% from the report before. At the average daily volume of 216,970 shares, buying them all back would take about 15.4 trading days (days to cover). See the history.
Which famous investors hold ODTX?
2 of the 50 well-known investors we track reported ODTX in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $2.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.